ĀÜĄņĀŅĀ×

Dr. Berrien-Elliott has over 10 years of experience in cytotoxic cellular immunotherapy and is a co-founder of Wugen. Dr. Berrien-Elliottā€™s interest is in translational immunology and immunotherapy. Dr. Berrien-Elliott has extensively studied in vivo memory NK cell differentiation in patients with hematologic malignancies. Dr. Berrien-Elliott is an Instructor of Medicine at Washington University School of Medicine.

Dr. Berrien-Elliott received her Ph.D. with honors from Saint Louis University School of Medicineā€™s Molecular Microbiology and Immunology Program. She conducted her post-doctoral training at Washington University School of Medicine in Dr. Fehnigerā€™s laboratory investigating NK cell immunotherapies and in vivo immune modulation in the context of clinical trials.